Trials / Completed
CompletedNCT02354898
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
A Phase I Study of BBI503 Monotherapy in Patients With Advanced Solid Tumors, or BBI503 Plus Sorafenib Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Sumitomo Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, phase 1 dose escalation study of BBI503 monotherapy, or BBI503 in combination with Sorafenib. This study population is adult patients with advanced solid tumors in monotherapy, or adult patients with advanced hepatocellular carcinoma in combination therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BBI503 | |
| DRUG | Sorafenib | Sorafenib 400mg twice daily (800mg total daily dose) |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2018-10-01
- Completion
- 2018-10-01
- First posted
- 2015-02-03
- Last updated
- 2022-04-12
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02354898. Inclusion in this directory is not an endorsement.